YUNGJIN PHARM. CO., LTD
Financials
Valuation Metrics
YUNGJIN PHARM. CO., LTD's Market Cap is ₩1920B. At end of 2025 it was ₩3658B. Ranked #873 of 2,421 in KR market (top 36%), #462 of 781 on KOSPI (top 59%), #92 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 40%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 192.04B KRW | KR#873/2,421 Sec#92/231 |
| Revenue | 253.00B KRW | KR#910/2,421 Sec#47/231 |
| Net Income | -6.26B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 227.40B KRW | KR#1,221/2,421 Sec#87/231 |
| Net Assets | 86.16B KRW | KR#1,524/2,421 Sec#120/231 |
| Employees | 628 | KR#401/2,421 Sec#34/231 |
| Value | ||
| P/B | 2.23x | KR#1,997/2,421 Sec#150/231 |
| P/S | 0.76x | KR#1,199/2,421 Sec#62/231 |
| FCF Yield | 0.28% | KR#1,195/2,421 Sec#90/231 |
| Profitability | ||
| ROE | -7.26% | KR#1,871/2,421 Sec#135/231 |
| ROA | -2.75% | KR#1,815/2,421 Sec#127/231 |
| Op. Margin | -1.71% | KR#1,723/2,421 Sec#117/231 |
| Revenue Growth | 0.60% | KR#1,491/2,421 Sec#148/231 |
| Financial Health | ||
| Debt Ratio | 163.93% | KR#1,977/2,421 Sec#211/231 |
| Total Debt | 76.13B KRW | KR#831/2,421 Sec#54/231 |
| FCF | 545.9M KRW | KR#1,180/2,421 Sec#90/231 |
| Cash | 3.59B KRW | KR#2,120/2,421 Sec#199/231 |
| Current Ratio | 1.47x | KR#1,230/2,421 Sec#131/231 |
| Performance | ||
| 1Y Return | -47.89% | KR#2,009/2,421 Sec#178/231 |
| 1M Return | -13.29% | KR#2,202/2,421 Sec#185/231 |
| From 52W High | -54.74% | KR#1,638/2,421 Sec#123/231 |
| 1Y MDD | -52.21% | KR#1,081/2,421 Sec#89/231 |
| Trading | ||
| Volume | 133,473 shares | KR#645/2,421 Sec#56/231 |
| Trading Value | 139.7M KRW | KR#1,405/2,421 Sec#144/231 |
| Foreign Own. | 2.85% | KR#1,335/2,421 Sec#120/231 |
| Per Share | ||
| EPS | -34 KRW | KR—/2,421 Sec—/231 |
| BPS | 471 KRW | KR#2,387/2,421 Sec#225/231 |
Company Info
Youngjin Pharm was established in 1962 for pharmaceutical manufacturing and sales, and listed in 1973, playing a pivotal role as an affiliate of the KT&G Group. The company sells specialty pharmaceuticals such as 'Harmonylan' and 'Fivero', exports antibiotics and raw materials, and aims to strengthen its competitiveness in domestic and international markets. Youngjin Pharm secures growth engines through R&D investment and leads fair and transparent ethical management via a self-compliance program and ISO37001 certification. Its headquarters are in Songpa-gu, Seoul Metropolitan City.